Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
The Food and Drug Administration (FDA) has granted Fast Track designation to RDD-0315, a novel topical gel for the treatment of fecal incontinence in spinal cord injury patients. RDD-0315 contains the alpha-agonist oxymetazoline in a topical gel formulation; it works by contracting the internal anal sphincter muscle. In a randomized, controlled crossover study involving 19 patients with spinal cord injury, the investigational gel was found to be beneficial, due to the local effect of oxymetazoline; a statistically significant reduction in the number of fecal incontinence episodes was observed 8 hours and 12 hours post-administration. Read more.
Source: MPR, February 15, 2019
Detecting bacterial infestations within the GI system, particularly using low cost methods, takes so much time that treatment is often administered too late. Clostridium difficile (C. diff) is a particular nasty nuisance that kills many frail patients, and even with a hospital lab it can take up to two days to get the results. Researchers at Chinese University of Hong Kong (CUHK) have developed fluorescent microrobots that can spot C. diff in a stool sample within a matter of minutes without relying on expensive laboratory equipment. Read more.
Source: Medgadget, February 15, 2019
With IlliniCare Health holding fast to its drastic cuts to reimbursement for incontinence supplies, ActivStyle has taken a hard a line. In November, the provider—the state’s largest provider of the supplies—announced it would no longer participate in the payer’s network, something it had done since 2011, says CEO Gayle Devin. “After fighting the fight, we made the decision that we can’t continue to operate at a loss here,” she said. “We labored long and hard over the decision, but if pulling out will help our cause (so be it).” IlliniCare, a Medicaid managed care payer, announced across-the-board cuts to DME and supplies of up to 50% in September 2017, effective Jan. 1, 2018. Concessions were made for other product categories, but not incontinence, despite evidence that providing the right products for patients saves money, says Devin. Read more.
Source: HME News, January 30, 2019
Nearly 50 million Americans wake up to urinate more than once per night due to a treatable medical condition called nocturia. A new awareness campaign called ‘Sleep Normal’ launched on Monday to raise awareness of nocturia, an underdiagnosed, treatable, medical condition that forces a person to wake more than once a night to urinate. Most people have never heard of nocturia and think it is a normal part of aging, despite the negative impact interrupted sleep can have on health. The ‘Sleep Normal’ campaign urges people to talk with their doctors about addressing frequent nighttime urination. ‘Sleep Normal’ is a collaboration between Avadel Pharmaceuticals and the recently formed Nocturia Council, which includes American Alliance for Healthy Sleep, Caregiver Action Network, HealthyWomen, Men’s Health Education Council, Men’s Health Network, Multiple Sclerosis Association of America, National Association for Continence, National Sleep Foundation, Simon Foundation for Continence and ZERO – The End of Prostate Cancer. Read more.
Source: UroToday, January 24, 2019
Accessible toileting specialist Closomat has highlighted the importance of Changing Places facilities for disabled people, following the Government’s proposals to increase the number of Changing Places toilets in the UK. Around 6 million people in the UK are affected by continence issues, according to the latest figures from the NHS. For many, conventional ‘away from home’ toilets are still not suitable; they need more space, and/or equipment – a Changing Places toilet. Changing Places toilets are wheelchair-accessible units that are spacious and include a bench and hoist, which allow disabled people to use the toilet with dignity. It can help people with a wide range of disabilities, including people living with stroke, continence issues, cerebral palsy, arthritis and multiple sclerosis. Read more.
Source: ATtoday, January 21, 2019
London researchers are zeroing in on the potential psychological effects of complications from women’s incontinence surgery, uncovering an increased risk of depression and self-harm after the corrective surgery. Researchers at the Western University branch of Toronto-based Institute for Clinical Evaluative Sciences and Lawson Health Research Institute — the research arm of the London Health Sciences Centre and St. Joseph’s Health Care London — examined patient outcomes after pelvic mesh implants from January 2004 to December 2012. Using 12 years of data from Ontario’s public health-care system, researchers studied the files of 57,611 women who underwent the midurethral mesh sling procedure during the study period. Of those, 1,586 went under the knife again to correct a complication from the mesh. Read more.
Source: The London Free Press, January 9, 2019
InControl Medical is proud to announce that Attain, the most advanced over-the-counter device available to treat male and female incontinence and the logical first choice for treatment, will be shown at the 2019 Consumer Electronics Show (CES, January 8-11, Las Vegas Sands, Halls A-D – 43569). According to Herschel “Buzz” Peddicord, InControl’s founder and CEO, “This revolutionary medical device is designed to help treat the approximately 87 million people in the U.S. suffering with stress, urge, or mixed urinary incontinence, and/or bowel incontinence. Attain provides muscle stimulation, visual biofeedback, and a guided exercise program to solve incontinence at the source — the muscle level. Attain’s regular self-treatment program, in the privacy of one’s home, eliminates the need for pads, meds, surgery or diapers.” Read more.
Source: Business Wire, January 8, 2019